Actuate Therapeutics, Inc. Common stock fell 11.6% on Thursday, November 5, 2026, on 524,900 shares. The headline around the move:
Actuate Therapeutics, Inc. Common stock (ACTU:NASDAQ) closed at $0.302 on November 11, 2026, up 1.75% on the day. The stock trades 96.2% below its 52-week high of $7.90 and 4.2% above its 52-week low of $0.290. Over the past year, it lost 94.9%. Actuate Therapeutics, Inc. Common stock is part of the Health Care sector.
In 252 trading sessions since November 11, 2025, ACTU closed higher on 102 days (40%). Its best day was August 25, 2026 (+28.46%) and its worst was October 13, 2026 (-27.64%). The stock moved 10% or more in a single session 37 times. It opened at least 5% above the previous day's high 3 times.
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU).
Find more stocks like ACTU with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.